Aminophylline for treating asthma and chronic obstructive pulmonary disease

References

• Weinberger M, Hendeles L. Theophylline in asthma. N. Engl. J. Med.334(21), 1380–1388 (1996).
   PubMed Web of Science ®Google Scholar
• Ward AJ, McKenniff M, Evans JM, Page CP, Costello JF. Theophylline: an immunomodulatory role in asthma? Am. Rev. Respir. Dis.147(3), 518–523 (1993).
   PubMed Web of Science ®Google Scholar
• Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma demonstration by withdrawal of therapy. Am. J. Respir. Crit. Care Med.151(6), 1907–1914 (1995).
   PubMedGoogle Scholar
• Kawai M, Kato M. Theophylline for the treatment of bronchial asthma: present status. Methods Find. Exp. Clin. Pharmacol.22(5), 309–320 (2000).
   PubMedGoogle Scholar
• Herrmann G, Aynesworth MB, Martin J. Successful treatment of persistent extreme dyspnea “status asthmaticus”: use of theophylline ethylenediamine intravenously. J. Lab. Clin. Med.23, 135–148 (1937).
   Google Scholar
• Aubier M, De Troyer A, Sampson M, Macklem PT, Roussos C. Aminophylline improves diaphragmatic contractility. N. Engl. J. Med.305(5), 249–252 (1981).
   PubMed Web of Science ®Google Scholar
• Kolbeck RC, Speir WA Jr, Carrier GO, Bransome ED Jr. Apparent irrelevance of cyclic nucleotides to the relaxation of tracheal smooth muscle induced by theophylline. Lung156(3), 173–183 (1979).
   PubMedGoogle Scholar
• Higbee MD, Kumar M, Galant SP. Stimulation of the endogenous cathecolamine release by theophylline: a proposed additional mechanism of action for theophylline effects. J. Allergy Clin. Immunol.70(5), 377–382 (1982).
   PubMed Web of Science ®Google Scholar
• Horrobin DF, Manku MS, Franks DJ, Hamet P. Methyl xanthine phosphodiesterase inhibitors behave as prostoglandin antagonists in a perfused rat mesenteric artery preparation. Prostoglandins13(1), 33–40 (1977).
   PubMed Web of Science ®Google Scholar
• Nicholson CD, Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm. Pharmacol.7(1), 1–17 (1994).
   PubMedGoogle Scholar
• Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc. Natl Acad. Sci. USA99(13), 8921–8926 (2002).
   PubMed Web of Science ®Google Scholar
• Foukas LC, Daniele N, Ktori C et al. Direct effects of caffeine and theophylline on the p110d and other phosphoinositiode 3 kinases; differential effects on lipid kinase and protein kinase activities. J. Biol. Chem.277(40), 37124–37130 (2002).
   PubMed Web of Science ®Google Scholar
• Fredholm BB. Theophylline actions on adenosine receptors. Eur. J. Respir. Dis. Suppl.109, 29–36 (1980).
   PubMedGoogle Scholar
• El-Hashim A, D’Agostino B, Matera MG, Page C. Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. Br. J. Pharmacol.119(6), 1262–1268 (1996).
   PubMed Web of Science ®Google Scholar
• Bjorck T, Gustaffsson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotriens and histamine. Am. Rev. Respir. Dis.145(5), 1087–1091 (1992).
   PubMed Web of Science ®Google Scholar
• Cushley MJ, Tattersfield AE, Holgate ST. Adenosine-induced bronchoconstricition in asthma. Antagonism by inhaled theophylline. Am. Rev. Respir. Dis.129(3), 380–384 (1984).
   PubMed Web of Science ®Google Scholar
• Mann JS, Holgate ST. Specific antagonism of adenosine-induced bronchoconstriciton in asthma by oral theophylline. Br. J. Clin. Pharmacol.19(5), 685–692 (1985).
   Google Scholar
• Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J.8(7), 1179–1183 (1995).
   PubMed Web of Science ®Google Scholar
• Markham A, Faulds D. Theophylline: a review of its potential steroid sparing effects in asthma. Drugs56(6), 1081–1091 (1998).
   PubMed Web of Science ®Google Scholar
• Jaffar Z, Sullivan PJ, Page CP, Costello JF. Low dose theophylline therapy modulates T-lymphocyte activity in subjects with atopic asthma. Eur. Resp. J.9(3), 456–463 (1996).
   PubMed Web of Science ®Google Scholar
• Shohat B, Volovitz B, Varsano I. Induction of suppressor T cells in asthmatic children by theophylline treatment. Clin. Allergy13(5), 487–493 (1983).
   Google Scholar
• Fink G, Mittelman M, Sholat B, Spitzer SA. Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin. Allergy17(4), 313–316 (1987).
   Google Scholar
• Page CP. Recent advances in our understanding of the use of theophylline in the treatment of asthma. J. Clin. Pharmacol.39(3), 237–240 (1999).
   Google Scholar
• Finnerty JP, Lee C, Wilson S, Madden J, Djukanovic R, Holgate ST. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo controlled parallel group study. Eur. Respir. J.9(8), 1672–1677 (1996).
   PubMed Web of Science ®Google Scholar
• Ohta K, Sawamoto S, Nakajima M et al. The prolonged survival of human eosinophils with interleukin-5 and its inhibition by theophylline via apoptosis. Clin. Exp. Allergy26(Suppl. 2), 10–15 (1996).
   Google Scholar
• Spoelstra FM, Berends C, Dijkhuizen B, de Monchy JG, Kauffman HF. Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro. Eur. Respir. J.12(3), 585–591 (1998).
   Google Scholar
• Mascali JJ, Cvietusa P, Negri J, Borish L. Antiinflammatory effects of theophylline: modulation of cytokine production. Ann. Allergy Asthma Immunol.77(1), 34–38 (1996).
   PubMed Web of Science ®Google Scholar
• Punnonen J, de Wall Malefty R, van Vlasselaer P. IL-10 and viral IL-10 prevent IL-4 induced IgE synthesis by inhibiting the accessory cell function of monocytes. J. Immunol.151(3), 1280–1289 (1993).
   PubMed Web of Science ®Google Scholar
• Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction tolerance. J. Immunol.151(5), 2390–2398 (1993).
   PubMed Web of Science ®Google Scholar
• Kroon LA. Drug interactions with smoking. Am. J. Health Syst. Pharm.64(18), 1917–1921 (2007).
   PubMed Web of Science ®Google Scholar
• Mcelnay JC, Smith GD, Helling DK. A practical guide to interactions involving theophylline kinetics. Drug Intell. Clin. Pharm.16(7–8), 533–542 (1982).
   PubMedGoogle Scholar
• Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab. Dispos.35(1), 79–85 (2007).
   PubMed Web of Science ®Google Scholar
• Weinberger MW, Matthay RA, Ginchansky EJ, Chidsey CA, Petty TL. Intravenous aminophylline dosage: use of serum theophylline measurement for guidance. JAMA235(19), 2110–2113 (1976).
   PubMed Web of Science ®Google Scholar
• Zaske DE, Miller KW, Strem EL, Austrian S, Johnson PB. Oral aminophylline therapy: increased dosage requirements in children. JAMA237(14), 1453–1455 (1977).
   PubMed Web of Science ®Google Scholar
• Ohnishi A, Kato M, Kojima J, Ushiama H, Yoneko M, Kawai H. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging20(1), 71–84 (2003).
   PubMed Web of Science ®Google Scholar
• Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet.45(10), 1013–1034 (2006).
   PubMed Web of Science ®Google Scholar
• Cusack B, Kelly JG, Lavan J, Noel J, O’Malley K. Theophylline kinetics in relation to age: the importance of smoking. Br. J. Clin. Pharmacol.10(2), 109–114 (1980).
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin. Pharmacol. Ther.24(4), 405–410 (1978).
   PubMedGoogle Scholar
• Grygiel JJ, Birkett DJ. Cigarette smoking and theophylline clearence and metabolism. Clin. Pharmacol. Ther.30(4), 491–496 (1981).
   PubMed Web of Science ®Google Scholar
• Frye RF, Zgheib NK, Matzke GR et al. Liver disease selectively modulated cytochrome P-450-mediated metabolism. Clin. Pharmacol. Ther.80(3), 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Mangione A, Imhoff TE, Lee RV, Shum LY, Jusko WJ. Pharmacokinetics of theophylline in hepatic disease. Chest73(5), 616–622 (1978).
   PubMed Web of Science ®Google Scholar
• Self TH, Chafin CC, Soberman JE. Effect of disease states on theophylline serum concentrations: are we still vigilant? Am. J. Med. Sci.319(3), 177–182 (2000).
   PubMed Web of Science ®Google Scholar
• Vozeh S, Powell JR, Riegelman S, Costello JF, Sheiner LB, Hopewell PC. Changes in theophylline clearance during acute illness. JAMA240(17), 1882–1884 (1978).
   PubMed Web of Science ®Google Scholar
• Itazawa T, Adachi Y, Nakabayashi M, Fuchizawa T, Murakami G, Miyawaki T. Theophylline metabolism in acute asthma with MxA-indicated viral infection. Pediatr. Int.48, 54–57 (2006).
   Web of Science ®Google Scholar
• Odajima Y. Examination of theophylline pharmacokinetics during an attack of bronchial asthma in children. Arerugi41(1), 22–28 (1992).
   Google Scholar
• Resar RK, Walson PD, Fritz WL, Perry DF, Barbee RA. Kinetics of theophylline variability and effect of arterial pH in chronic obstructive lung disease. Chest76(1), 11–16 (1979).
   PubMed Web of Science ®Google Scholar
• Ohnishi A. A review of clinical use of theophylline in acute asthma: factors influencing kinetic disposition and drug interactions. Methods Find. Exp. Clin. Pharmacol.22(4), 253–258 (2000).
   PubMedGoogle Scholar
• Thomson NC. Asthma therapy: theophylline. Can. Respir. J.5(Suppl. A), A60–A63 (1998).
   Google Scholar
• Mitra A, Bassler D, Goodman K, Lasserson TJ, Ducharme FM. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst. Rev. (2), CD001276 (2005).
   Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of randomized controlled trials: is blinding necessary? Control. Clin. Trials17(1), 1–12 (1996).
   PubMedGoogle Scholar
• Becker AB, Nelson NA, Simons ER. The pulmonary index assessment of a clinical score for asthma. Am. J. Dis. Child.138(6), 574–576 (1984).
   PubMedGoogle Scholar
• Bien JP, Bloom MD, Evans RL, Specker B, O’Brien KP. Intravenous theophylline in pediatric status asthmaticus. A prospective, randomized, double-blind, placebo-controlled trial. Clin. Pediatr. (Phila.)34(9), 475–481 (1995).
   PubMed Web of Science ®Google Scholar
• Carter E, Cruz M, Chesrown S, Shieh G, Reilly K, Hendeles L. Efficacy of intravenously administered theophylline in children hospitalised with severe asthma. J. Pediatr.122(3), 470–476 (1993).
   PubMed Web of Science ®Google Scholar
• DiGiulio GA, Kercsmar CM, Krug SE, Alpert SE, Marx CM. Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. J. Pediatr.122(3), 464–469 (1993).
   PubMed Web of Science ®Google Scholar
• Nuhoglu Y, Dai A, Barlan IB, Baaran MM. Efficacy of aminophylline in the treatment of acute asthma exacerbation in children. Ann. Allergy Asthma Immunol.80(5), 395–398 (1998).
   PubMed Web of Science ®Google Scholar
• Strauss RE, Wertheim DL, Bonagura VR, Valacer DJ. Aminophylline therapy does not improve outcome and increases adverse events in children hospitalized with acute asthmatic exacerbations. Pediatrics93(2), 205–210 (1994).
   PubMed Web of Science ®Google Scholar
• Wood DW, Downes JJ, Leeks HI. A clinical scoring system for the diagnosis of respiratory failure. Am. J. Dis. Child.123(3), 227–228 (1972).
   PubMedGoogle Scholar
• Yung M, South M. Randomized controlled trial of aminophylline for severe acute asthma. Arch. Dis. Child.79(5), 405–410 (1998).
   PubMed Web of Science ®Google Scholar
• Bishop J, Carlin J, Nolan T. Evaluation of the properties and reliability of a clinical severity scale for acute asthma in children. J. Clin. Epidemiol.45(1), 71–76 (1992).
   PubMed Web of Science ®Google Scholar
• Needleman JP, Kaifer MC, Nold JT, Shuster PE, Redding MM, Gladstein J. Theophylline does not shorten hospital stay for children admitted for asthma. Arch. Pediatr. Adolesc. Med.149(2), 206–209 (1995).
   PubMedGoogle Scholar
• Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to β-2 agonists in adults with acute asthma. Cochrane Database Syst. Rev. (4), CD002742 (2000).
   Google Scholar
• Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled β-adrenergic agonist in the treatment of acute asthma exacerbations. Am. Rev. Respir. Dis.132 (2), 283–286 (1985).
   PubMed Web of Science ®Google Scholar
• Emerman CL, Crafford WA, Vrobel TR. Ventricular arrhythmias during treatment for acute asthma. Ann. Emerg. Med.15(6), 699–702 (1986).
   Google Scholar
• Wrenn K, Slovis CM, Murphy F, Greenberg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann. Int. Med.115(4), 241–247 (1991).
   PubMed Web of Science ®Google Scholar
• Huang D, O’Brien RG, Harman E et al. Does aminophylline benefit adults admitted to the hospital for an acute exacerbation of asthma? Ann. Int. Med.119(12), 1155–1160 (1993).
   Google Scholar
• Murphy DG, McDermott MF, Rydman RJ, Sloan EP, Zalenski RJ. Aminophylline in the treatment of acute asthma when β-2 adrenergics and steroids are provided. Arch. Int. Med.153(15), 1784–1788 (1993).
   PubMedGoogle Scholar
• Coleridge J, Cameron P, Epstein J, Teichtahl H. Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators. Aust. NZ J. Med.23(4), 348–354 (1993).
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax59(Suppl. 1), 1–232 (2004).
   Google Scholar
• McKenzie DK, Frith PA, Burdon JG, Town GI; Australian Lung Foundation; Thoracic Society of Australia and New Zealand. The COPDX plan: Australian and New Zealand guidelines for the management of COPD 2003. Med. J. Aust.178(Suppl.), S7–S39 (2003).
   PubMed Web of Science ®Google Scholar
• Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ327(7416), 643–648 (2003).
   PubMed Web of Science ®Google Scholar
• Duffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax60(9), 713–717 (2005).
   Google Scholar
• Chen CY, Yang KY, Lee YC, Perng PP. Effect of oral aminophylline on pulmonary function improvement and tolerability in different age groups of COPD patients. Chest128(4), 2088–2092 (2005).
   Google Scholar
• Inoue H, Yamauchi K, Kobayashi H, Tanifuji Y. The efficacy of intravenous theophylline injection for treatment of acute exacerbations of bronchial asthma. Arerugi51(4), 379–382 (2002).
   Google Scholar
• Yamauchi K, Kobayashi H, Tanifuji Y, Yoshida T, Pian HD, Inoue H. Efficacy and safety of intravenous theophylline administration for treatment of mild acute exacerbation of bronchial asthma. Respirology10(4), 491–496 (2005).
   Google Scholar